Growth Disorders

28 July 2017
medwireNews: Data from a dose-escalation study of the long-acting growth hormone (GH) somapacitan support its further development as a weekly treatment in children with GH deficiency (GHD), say researchers. The medication, which is currently being tested in a phase III trial in adults and a phase II trial in children, reversibly binds to... Read More
30 June 2017
medwireNews: Weekly injection of a pegylated recombinant human growth hormone (PEG-rhGH) has proved effective in a study of Chinese children with GH deficiency (GHD). The publication details results from a phase II study, which established the superiority of the 0.2 mg/kg per week dose over the 0.1 mg/kg per week dose, and of a phase III study... Read More
01 June 2017
medwireNews: A substantial proportion of children with isolated growth hormone deficiency (IGHD) have a normal result when retested just 1 year later, report researchers. By contrast, all the 95 patients in their study who had multiple pituitary hormone deficiency still had a subnormal GH stimulation response when retested after 1 year of GH... Read More
28 April 2017
medwireNews: Researchers have calculated the optimal times to take blood samples for measuring insulin-like growth factor (IGF)-1 levels in children with growth hormone deficiency (GHD) receiving the long-acting growth hormone MOD-4023. Peak IGF-1 is best determined on day 2 after MOD-4023 dosing, but mean IGF-1 is better determined on day 4,... Read More
31 March 2017
medwireNews: Analysis of the KIGS database confirms the beneficial effects of recombinant human growth hormone (rhGH) on height and weight in children with Prader–Willi syndrome (PWS). Nienke Bakker (Dutch Growth Research Foundation, Rotterdam) and colleagues studied two groups of PWS patients: 522 who received at least 3 years of rhGH... Read More
01 March 2017
medwireNews: The long-acting TransCon growth hormone (GH) has shown comparable efficacy and safety to standard daily somatropin in children with GH deficiency (GHD) in a phase II trial. TransCon GH consists of GH transiently bound to methoxypolyethylene glycol by a proprietary linker, allowing the active drug to be released over the course of... Read More